Therefore, although targeting IL-33/ST2 is a potential treatment for a variety of diseases, including cancers, greater understanding of the mechanisms of the IL-33/ST2 pathway in macrophage polarization is required before clinical applications can be considered. The gene discussed is IL33; the disease is cancer.